One compound, Spiroleiferthione A, showed moderate, dose-dependent inhibition of human kidney cell proliferation induced by high glucose in an in vitro assay.
Pharmaceuticals · 7 authors, 3 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
One compound, Spiroleiferthione A, showed moderate, dose-dependent inhibition of human kidney cell proliferation induced by high glucose in an in vitro assay.
Their structures were elucidated using spectroscopic data, NMR calculations, electronic circular dichroism, and X-ray diffraction. Spiroleiferthione A was identified as a rare 2-thiohydantoin with a novel spirocyclic structure. Bioactivity testing focused on a single in vitro assay, where Spiroleiferthione A demonstrated moderate, dosage-dependent inhibitory activity against high glucose-induced proliferation of human renal mesangial cells. The study's limitations include the restriction to in vitro testing, the lack of investigation into in vivo efficacy or mechanism for the diabetic nephropathy model, and the evaluation of only two compounds.